Litcius/Paper detail

Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells

Da Som Kim, Kyoungmi Min, Suk Kyeong Lee

2020Anticancer Research40 citationsDOIOpen Access PDF

Abstract

BACKGROUND/AIM: 5-Fluorouracil (5-FU) is an anticancer drug commonly used to treat gastric cancer; however, continuous 5-FU chemotherapy causes drug resistance. MATERIALS AND METHODS: We established five sublines of 5-FU-resistant AGS gastric cancer cells to investigate changes that may have occurred in the development of 5-FU resistance. Drug resistance to other chemotherapeutic reagents, proliferation, cell-cycle changes, and wound healing ability were assessed for each subline. RESULTS: phase arrest, up-regulation of p57, and down-regulation of cyclin D1 were commonly observed in all five sublines. Resistance to paclitaxel and cisplatin was also observed in most of the sublines. CONCLUSION: arrest due to changes in p57 and cyclin D1 expression may confer drug resistance, while EMT seems non-essential to 5-FU resistance in AGS gastric carcinoma cells.

Topics & Concepts

CisplatinPaclitaxelCyclin D1Drug resistanceCancerCell cycleCancer researchChemotherapyFluorouracilCell growthBiologyCancer cellMedicinePharmacologyInternal medicineMicrobiologyGeneticsGastric Cancer Management and OutcomesCancer-related Molecular PathwaysCancer Cells and Metastasis
Cell Cycle Dysregulation Is Associated With 5-Fluorouracil Resistance in Gastric Cancer Cells | Litcius